{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:56:44Z","timestamp":1790690204433,"version":"4.1.0"},"reference-count":75,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Intern Med"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pharmacological agents that inhibit enzymes of the B\u2010cell receptor (<jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>) pathway are of increasing importance in the treatment of B\u2010cell malignancies. These include inhibitors of Bruton tyrosine kinase (<jats:styled-content style=\"fixed-case\">BTK<\/jats:styled-content>), phosphatidylinositol 3\u2010kinase (<jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>3K), splenic tyrosine kinase and protein kinase C\u03b2. Two agents are already approved in the <jats:styled-content style=\"fixed-case\">USA<\/jats:styled-content> and Europe: ibrutinib, a <jats:styled-content style=\"fixed-case\">BTK<\/jats:styled-content> inhibitor, for the treatment of chronic lymphatic leukaemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>), mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>) and Waldenstr\u00f6m's macroglobulinemia; and idelalisib, a <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>3K\u03b4 inhibitor, for the treatment of <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> and follicular lymphoma. In addition, the role of these drugs in diffuse large B\u2010cell lymphoma and marginal zone lymphoma is under investigation, as single agents and in combination with chemotherapy. In <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>, both ibrutinib and idelalisib have an established role as first\u2010line therapy in patients with del(17p), and in <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>, ibrutinib is a standard option for patients relapsing after chemoimmunotherapy. Unexpected toxicities have been encountered when combining these potent new agents with other drugs, including chemotherapy and lenalidomide, and based on this experience the risks and benefits of novel combinations must be evaluated carefully. In this review, we summarize the efficacy and safety results with these inhibitors and discuss novel combinations that are under study and the future role of <jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content> inhibitors in these disorders.<\/jats:p>","DOI":"10.1111\/joim.12600","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T02:46:40Z","timestamp":1489546000000},"page":"415-428","source":"Crossref","is-referenced-by-count":43,"title":["Targeting of B\u2010cell receptor signalling in B\u2010cell malignancies"],"prefix":"10.1111","volume":"282","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6707","authenticated-orcid":false,"given":"M.","family":"Jerkeman","sequence":"first","affiliation":[{"name":"Department of Oncology Lund University Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hallek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Cologne University Hospital Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III University of Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Hemato\u2010Oncology H\u00f4pital Saint\u2010Louis Assistance Publique\u2010H\u00f4pitaux de Paris (AP\u2010HP) Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kimby","sequence":"additional","affiliation":[{"name":"Hematology Center Department of Medicine Karolinska Institute Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Staudt","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2014.05.007"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236471"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-F"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547869"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0250-9"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203489"},{"key":"e_1_2_14_10_1","first-page":"1","article-title":"Anti\u2010tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO\/GS\u20104059, in combination with the glycoengineered type II anti\u2010CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in\u00a0vivo efficacy compared to ONO\/GS\u20104059 in combination with rituximab","author":"Yasuhiro T","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_14_11_1","first-page":"123","article-title":"PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL)","volume":"393","author":"Okkenhaug K","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271171"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2013.09.017"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0993-T"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0474"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716636542"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0071"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153205"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7171"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-603670"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-585869"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00465-9"},{"key":"e_1_2_14_27_1","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood.V126.23.2944.2944","article-title":"Comparing single\u2010agent Ibrutinib, Bendamustine plus Rituximab (BR) and Ibrutinib plus BR in patients with previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an indirect comparison of the RESONATE and HELIOS trials","volume":"126","author":"Hillmen P","year":"2015","journal-title":"Blood"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2809"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.263"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.08.006"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140806"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664086"},{"key":"e_1_2_14_35_1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood.V126.23.832.832","article-title":"The BTK inhibitor, Bgb\u20103111, is safe, tolerable, and highly active in patients with relapsed\/refractory B\u2010cell malignancies: initial report of a phase 1 first\u2010in\u2010human trial","volume":"126","author":"Tam C","year":"2015","journal-title":"Blood"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_2_14_38_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.LBA-5.LBA-5","article-title":"Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed\/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double\u2010blind placebo\u2010controlled study","volume":"126","author":"Zelenetz AD","year":"2015","journal-title":"Blood"},{"key":"e_1_2_14_39_1","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1182\/blood.V126.23.3928.3928","article-title":"Combination trial of duvelisib (IPI\u2010145) with bendamustine, rituximab, or bendamustine\/rituximab in patients with lymphoma or chronic lymphocytic leukemia","volume":"126","author":"Flinn IW","year":"2015","journal-title":"Blood"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595934"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-683516"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"e_1_2_14_46_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood.V124.21.78.78","article-title":"Mutational analysis of patients with primary resistance to single\u2010agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL)","volume":"124","author":"Balasubramanian S","year":"2014","journal-title":"Blood"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12434"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13149"},{"key":"e_1_2_14_50_1","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1200\/JCO.2016.34.15_suppl.7548","article-title":"The combination of ibrutinib and venetoclax (ABT\u2010199) to achieve complete remissions in patients with relapsed\/refractory mantle cell lymphoma: preliminary results of the phase II AIM study","volume":"34","author":"Tam CS","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-460832"},{"key":"e_1_2_14_52_1","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/jco.2013.31.15_suppl.8501","article-title":"Preliminary results of PI3K\u03b4 inhibitor idelalisib (GS\u20101101) treatment in combination with everolimus, bortezomib, or bendamustine\/rituximab in patients with previously treated mantle cell lymphoma (MCL)","volume":"31","author":"Wagner\u2010Johnston N","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_14_53_1","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood.V126.23.3935.3935","article-title":"Results of the mantle cell lymphoma subset from a phase 2a study of copanlisib, a novel PI3K inhibitor, in patients with indolent and aggressive lymphoma","volume":"126","author":"Cunningham D","year":"2015","journal-title":"Blood"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm463"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3937"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08638"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673236"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647834"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.018"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.10.005"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3146"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2525"},{"key":"e_1_2_14_65_1","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1182\/blood.V120.21.3663.3663","article-title":"Clinical safety and activity in a Phase 1 trial of IPI\u2010145, a potent inhibitor of phosphoinositide\u20103\u2010kinase\u2010\u03b4, \u03b3, in patients with advanced hematologic malignancies","volume":"120","author":"Flinn IW","year":"2012","journal-title":"Blood"},{"key":"e_1_2_14_66_1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood.V126.23.1493.1493","article-title":"An open\u2010label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B\u2010cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL)","volume":"126","author":"Younes A","year":"2015","journal-title":"Blood"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633156"},{"key":"e_1_2_14_69_1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood.V124.21.800.800","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial","volume":"124","author":"Bartlett NL","year":"2014","journal-title":"Blood"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-597914"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-718106"},{"key":"e_1_2_14_73_1","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1182\/blood.V124.21.4419.4419","article-title":"Phase 2 trial of entospletinib (GS\u20109973), a selective SYK inhibitor, in follicular lymphoma (FL)","volume":"124","author":"Sharman JP","year":"2014","journal-title":"Blood"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_2_14_76_1","article-title":"Single\u2010agent ibrutinib demonstrates efficacy and safety in patients with relapsed\/refractory marginal zone lymphoma: a multicenter, open\u2010label, phase 2 study","volume":"128","author":"Noy A","year":"2016","journal-title":"Blood"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjoim.12600","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/joim.12600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T14:20:35Z","timestamp":1695997235000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/joim.12600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/joim.12600"],"URL":"https:\/\/doi.org\/10.1111\/joim.12600","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,14]]}}}